NCT03814291View on ClinicalTrials.gov

A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

March 5, 2020

Study Completion Date

April 10, 2020

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

IBI302

0.05mg/eye;Intraocular injection

DRUG

IBI302

0.15mg/eye;Intraocular injection

DRUG

IBI302

0.5mg/eye;Intraocular injection

DRUG

IBI302

1mg/eye;Intraocular injection

DRUG

IBI302

2mg/eye;Intraocular injection

DRUG

IBI302

4mg/eye;Intraocular injection

Trial Locations (1)

200080

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT03814291 - A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter